Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 11/20 | 0.51 |
| ▸ | ITGA4 | P13612 | 11/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.42 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6343632 | 0.91 | ITGB1 (0.60) | ITGB1ITGA4POLBSMN1; SMN2ITGB3 | |
| SCHEMBL6343069 | 0.88 | ITGB1 (0.47) | ITGB1ITGA4POLBSMN1; SMN2ITGB3 | |
| SCHEMBL6340839 | 0.85 | ITGB1 (0.55) | ITGB1ITGA4POLBSMN1; SMN2ITGB3 | |
| SCHEMBL6344233 | 0.84 | ITGB1 (0.59) | ITGB1ITGA4POLBSMN1; SMN2ITGB7 | |
| SCHEMBL6340843 | 0.82 | ITGB1 (0.57) | ITGB1ITGA4POLBSMN1; SMN2ITGB3 | |
| SCHEMBL6346085 | 0.81 | ITGB1 (0.48) | ITGB1ITGA4POLBSMN1; SMN2ITGB3 | |
| SCHEMBL6344930 | 0.81 | POLB (0.52) | ITGB1ITGA4POLBSMN1; SMN2ITGB3 | |
| SCHEMBL6343898 | 0.81 | ITGB1 (0.63) | ITGB1ITGA4POLBSMN1; SMN2ITGB3 | |
| SCHEMBL6354846 | 0.81 | ITGB1 (0.49) | ITGB1ITGA4POLBSMN1; SMN2ITGB3 | |
| SCHEMBL6345390 | 0.81 | POLB (0.51) | ITGB1ITGA4POLBSMN1; SMN2ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040053907-A1 | Cell adhesion inhibitors | BIOGEN, INC. A MASSACHUSETTS CORPORATION. | 2004-03-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053907-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | ITGB1 11/4885ITGA4 37/4885POLB 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.